PMID- 17420111
OWN - NLM
STAT- MEDLINE
DCOM- 20080211
LR  - 20161124
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 61
IP  - 8
DP  - 2007 Sep
TI  - Significance of thyroid blood flow as a predictor of methimazole sensitivity in 
      untreated hyperthyroid patients with Graves' disease.
PG  - 472-6
AB  - OBJECTIVE: The peak systolic velocity (PSV) of the inferior thyroid artery (ITA) 
      is increased in untreated hyperthyroid patients with Graves' disease (GD). We 
      investigated the clinical significance of the ITA-PSV and its determinants in 
      hyperthyroid GD patients. PATIENTS AND METHODS: ITA-PSV, together with thyroid 
      volume, was measured by ultrasonography in untreated hyperthyroid GD patients 
      (n=49) and healthy subjects (n=22). Established markers of GD activity such as 
      TSH receptor antibody (TRAb), thyroid stimulating antibody (TSAb), vascular 
      endothelial growth factor (VEGF) and immunoglobulin E (IgE) were simultaneously 
      determined. RESULTS: ITA-PSV, thyroid volume, VEGF and IgE were significantly 
      higher in hyperthyroid GD patients than in normal subjects. ITA-PSV in 
      hyperthyroid GD patients was correlated positively with serum levels of FT(3), 
      FT(4) and IgE, smoking index and thyroid volume, and negatively with total, HDL- 
      and LDL-cholesterols, but did not correlate significantly with age, triglyceride, 
      TRAb, TSAb or VEGF. In stepwise regression analysis, ITA-PSV showed significant 
      positive and negative associations with IgE and LDL-cholesterol, respectively, in 
      hyperthyroid GD patients. In the pre-treatment hyperthyroid state, FT(4) and 
      ITA-PSV, but not IgE, were found to be significantly and positively associated 
      with the maintenance dose of methimazole (MMI) required to keep serum TSH within 
      normal range for at least 12 months. CONCLUSION: These results suggest that 
      ITA-PSV in untreated hyperthyroid GD patients may reflect GD activity and thus 
      MMI sensitivity.
FAU - Nagasaki, Toshiki
AU  - Nagasaki T
AD  - Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City 
      University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 
      545-8585, Japan.
FAU - Inaba, Masaaki
AU  - Inaba M
FAU - Kumeda, Yasuro
AU  - Kumeda Y
FAU - Fujiwara-Ueda, Misako
AU  - Fujiwara-Ueda M
FAU - Hiura, Yoshikazu
AU  - Hiura Y
FAU - Nishizawa, Yoshiki
AU  - Nishizawa Y
LA  - eng
PT  - Journal Article
DEP - 20070307
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antithyroid Agents)
RN  - 0 (Immunoglobulins, Thyroid-Stimulating)
RN  - 0 (Receptors, Thyrotropin)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 06LU7C9H1V (Triiodothyronine)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 554Z48XN5E (Methimazole)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antithyroid Agents/*therapeutic use
MH  - Blood Flow Velocity
MH  - Female
MH  - Graves Disease/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunoglobulins, Thyroid-Stimulating/blood
MH  - Male
MH  - Methimazole/*therapeutic use
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Receptors, Thyrotropin/immunology
MH  - Regional Blood Flow
MH  - Thyroid Gland/*blood supply/diagnostic imaging/pathology
MH  - Thyroxine/blood
MH  - Triiodothyronine/blood
MH  - Ultrasonography, Doppler
MH  - Vascular Endothelial Growth Factor A/blood
EDAT- 2007/04/11 09:00
MHDA- 2008/02/12 09:00
CRDT- 2007/04/11 09:00
PHST- 2007/01/20 00:00 [received]
PHST- 2007/02/06 00:00 [accepted]
PHST- 2007/04/11 09:00 [pubmed]
PHST- 2008/02/12 09:00 [medline]
PHST- 2007/04/11 09:00 [entrez]
AID - S0753-3322(07)00023-6 [pii]
AID - 10.1016/j.biopha.2007.02.002 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2007 Sep;61(8):472-6. doi: 10.1016/j.biopha.2007.02.002. 
      Epub 2007 Mar 7.